“`html
Hernexeos Shows Promise as First-Line Treatment for HER2-Mutated Lung Cancer
Table of Contents
A new study presented at the European Society for Medical Oncology (ESMO) Congress on Thursday, October 17, 2024, reveals highly encouraging results for Hernexeos (zongertinib) as a first-line treatment option for patients wiht non-small cell lung cancer (NSCLC) harboring HER2 mutations. While previously approved for patients who had undergone prior treatment, this data focuses on individuals beginning their cancer journey, offering a potential new hope for those with this aggressive form of the disease.
Breakthrough Data in a Challenging Subtype
HER2 mutations are relatively uncommon, affecting between 2% and 4% of NSCLC tumors.Though, these tumors are known to be especially aggressive and have a higher propensity for spreading to the brain, according to a presentation at the ESMO meeting. The phase 1b trial, involving 74 patients, demonstrated a remarkable objective response rate (ORR) of 77% and a disease control rate of 96%.
“Zongertinib given as a first-line therapy demonstrated significant and clinically meaningful benefit in treatment-naïve patients with advanced HER2-mutant NSCLC,” stated a lead researcher involved in the study. The rapid onset of response was also notable, with a median time to objective response of just 1.4 months.
Trial Details and Patient Characteristics
The phase 1b trial, led by Sanjay Popat, M.B.B.S., Ph.D.,of The Royal Marsden NHS Foundation Trust,enrolled a patient population largely comprised of older individuals,with 58% being 65 years or older.Approximately 35% of participants had a history of tobacco exposure,and around 30% had evidence of brain metastases at the study’s outset. The objective response rate – a key metric in cancer trials measuring tumor size reduction – served as the primary endpoint,with disease control,duration of response,and progression-free survival as secondary endpoints.
Further analysis revealed a six-month duration of response rate of 80% (95% CI, 65%-89%) with a median follow-up of 9.7 months. the median progression-free survival reached 11.6 months, with a six-month rate of 79%.
Managing Side Effects and Future Research
While a significant majority of patients (91%) experienced treatment-related side effects, these were generally mild. only 18% reported a grade 3 side effect on a scale of 1-5, and there were no reports of grade 4 or 5 adverse events. A small percentage of patients-15%-required a dose reduction of Hernexeos due to side effects, while 9% discontinued treatment altogether. Two cases of interstitial lung disease/pneumonitis were reported.
Building on these promising phase 1b results,enrollment has begun in a phase 3 randomized controlled trial,known as Beamion LUNG-2. This larger study will further evaluate the efficacy and safety of Hernexeos in this patient population.
HER2 Mutation Specificity
Approximately two-thirds of the patients enrolled in the study carried the A775_G776insYVMA type of HER2 mutation. Importantly, the data indicated that patients with both this specific mutation and other HER2 alterations experienced benefits from Hernexeos treatment, suggesting a broad potential applicability within the HER2-mutated NSCLC landscape.
These findings represent a significant step forward in the treatment of a particularly challenging subtype of lung cancer, offering renewed optimism for patients and driving further research into targeted therapies.
